Less than one in 10 patients that would benefit from GLP-1 drugs like Wegovy are able to get them, caution the World Health Organization as it releases its initial advice on the therapies.
Considering more than one billion people worldwide now classified as obese, it is advocating for increased and just access to this class of drugs.
According to forecasts, over two billion are projected to be obese by 2030 unless action is taken.
"The latest guidance recognises that excess weight is a long-term condition that can be addressed with holistic and ongoing care," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are significant barriers to widespread availability to the treatments that can help people shift significant weight, says the organization.
Skinny Jab Shortage
Despite the current most optimistic scenario, the supply of these medications could only cover about 100 million people – less than 10% of those who need them, per the WHO.
The advice encourages countries and companies to increase access, through strategies like voluntary licensing.
Exclusive production rights on semaglutide – the core ingredient of a leading brand – is due to expire in a number of countries in 2026.
The Way Weight-Loss Drugs Function
GLP-1 drugs imitate a natural hormone to slow digestion, curb appetite and boost feelings of fullness so users eat less.
People commonly begin shedding pounds in the initial weeks of commencing the once-weekly jabs.
Research suggests people may regain a significant portion a year later of halting the medication, as their normal appetite return.
To be carrying excess weight increases your likelihood for contracting health problems, including diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight impacts people in every country and was responsible for millions of fatalities worldwide in 2024, per the health agency.
